Phase 1 trial of recombinant human interleukin-1β (rhIL-1β), carboplatin, and etoposide in patients with solid cancers: Southwest oncology group study 8940

Cancer Investigation

Volumn 15, Issue 5, 1997, Pages 403-410

  Rinehart, John ^a,g   Hersh, Evan ^b   Issell, Brian ^c   Triozzi, Pierre ^d   Buhles, William ^e   Neidhart, James ^f  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^e ROCHE BIOSCIENCE   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

^g SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE; RECOMBINANT INTERLEUKIN 1BETA;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TOXICITY TESTING;

EID: 0030766190     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709047578     Document Type: Article

References (42)

1. Dinarello CA: Interleukin-1 and interleukin-1 antagonism. Blood 77:1627-1652, 1991.
2. Platanias LC, Vogelzang NJ: Biology, pathophysiology, and clinical prospects. Am J Med 89:621-629, 1990.
3. Oppenheim JJ, Kovacs EJ, Matsushima K, et al: There is more than one interleukin-1. Immunol Today 7:45-50, 1986.
4. Neta N, Oppenheim J: IL-1: Can We Exploit Jekyll and Subjugate Hyde? Biologic Therapy of Cancer Updates, Philadelphia, Lippincott, No. 10, October 1992.
5. Colotta F, Re F, Muzio M, et al: Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science 261:472-475, 1993.
6. Brugger W, Macklin W, Heimfeld S, et al: Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 β(IL-1β), IL-6, IL-3, interferon-γ, erythropoietin. Blood 81:2579-2854, 1993.
7. Muench MO, Firpo MT, Moore MAS: Bone marrow transplantation with Interleukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential. Blood 81:3463-3473, 1993.
8. Fibbe WE, Falkenburg JHF, Schaafsma MR: The hematopoietic activities of interleukin-1. Biotherapy 1:263-271, 1989.
9. Zesbo KM, Yuschenkoff VN, Schiffer S, et al: Vascular endothelial cells and granulopoiesis: Interleukin-1 stimulates release of G-CSF and GM-CSF. Blood 71:99-103, 1988.
10. Neta R, Stein MB, Oppenheim JJ, et al: The in vivo effects of interleukin-1. Bone marrow cells are induced to cycle after administration of interleukin-1. J Immunol 139:1861-1866, 1987.
11. Bagby GC Jr: Interleukin-1 and hematopoiesis. Blood Rev 3:152-161, 1989.
12. Broxmeyer HE, William DE, Lu L, et al: The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: Synergism of tumor necrosis factor and interferon-γ. J Immunol 136:4487-4495, 1986.
13. Kurland JL, Broxmeyer HE, Pelus LM, et al: Role for monocyte-macrophage-derived colony-stimulating factor and prostaglandin E in the positive and negative feedback control of myeloid stem cell proliferation. Blood 52:388-407, 1978.
14. O'Reilly M, Gamelli RL: Indomethacin augments granulocyte-macrophage colony-stimulating factor-induced hematopoiesis following 5FU treatment. Exp Hematol 18:974-978, 1990.
15. Hino M, Tojo A, Miyazono K, et al: Effects of type β transforming growth factor on haematopoietic progenitor cells. Br J Haematol 70:143-147, 1988.
16. Keller JR, Mantel C, Sing G, et al: Transforming growth factor β 1 selectively regulates early murine hematopoietic progenitors and inhibits the growth of IL-3 dependent myeloid leukemia cell lines. J Exp Med 168:737-744, 1988.
17. Wolpe SD, Cerami A: Macrophage inflammatory proteins 1 and 2 members of a novel superfamily of cytokines. FASEB J 3:2565-2573, 1989.
18. Broxmeyer HE, Sherry B, Lu L, et al: Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation in vitro by bone marrow myeloid progenitor cells. Blood 6:1110-1116, 1990.
19. Klimpel GR, Fleischmann R, Kimpel KD: Gamma interferon (Ifn γ) and Ifn γ suppress murine myeloid colony formation (CFU-C): Magnitude of suppression is dependent upon level of colony-stimulating factor (CSF). J Immunol 129:76-80, 1982.
20. Raefsky EL, Platanias LC, Zoumbos NC, et al: Studies of interferon as a regulator of hematopoietic cell proliferation. J Immunol 135:2507-2512, 1985.
21. Rigby WFC, Ball ED, Guyre PM, et al: The effect of recombinant DNA derived interferons on the growth of myeloid progenitor cells. Blood 65:858-861, 1985.
22. Graham GJ, Pragnell IB: Negative regulators of hemopoieses - Current advances. Prog Growth Factor Res 2:181-192, 1990.
23. Gasparetto C, Laver J, Abboud M, et al: Effects of interleukin-1 on hematopoietic progenitors: Evidence of stimulatory and inhibitory activities in a primate model. Blood 74:547-550, 1989.
24. Constine LS, Harwell BA, Keng P, et al: Interleukin 1 alpha stimulates hematopoiesis but not tumor cell proliferation and protects mice from lethal total body irradiation. Int J Radiat Oncol Biol Phys 20:447-656, 1991.
25. Moore MAS, Warren DJ: Synergy of interleukin 1 and granulocyte colony-stimulating factor: In vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc Natl Acad Sci USA 84: 7134-7138, 1987.
26. Eppstein DA, Kurahara CG, Bruni NA, et al: Prevention of doxorubicin-induced hematotoxicity in mice by interleukin-1. Cancer Res 49:3955-3960, 1989.
27. Futami H, Jansen R, Macphee MJ, et al: Chemoprotective effects of recombinant human IL-1α in cyclophosphamide-treated normal and tumor-bearing mice. J Immunol 145:4121-4130, 1990.
28. Stork L, Barczuk L, Kissinger M, et al: Interleukin-1 accelerates murine granulocyte recovery following treatment with cyclophosphamide. Blood 73:938-944, 1989.
29. Fibbe WE, van der Meer JWM, Falkenburh JHF, et al: A single low dose of human recombinant interleukin 1 accelerates the recovery of neutrophils in mice with cyclophosphamide-induced neutropenia. Exp Hematol 17:805-808, 1989.
30. Hornung R, Longo D: Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high dose cyclophosphamide therapy. Blood 80:77-83, 1992.
31. Damia G, Komschlies K, Wiltrout R: Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: Protection from hematological and non-hematological toxicities. Cancer Res 52:4082-4089, 1992.
32. Castelli M, Block P, Talmadge J: Protective, restorative, and therapeutic properties of recombinant human IL-1 in rodent models. J Immunol 140:3830-3837, 1988.
33. Crown J, Jakubowski A, Kemeny N, et al: A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of S-fluorouracil in patients with gastrointestinal cancer. Blood 78(6):1420-1427, 1991.
34. Smith JW 2d, Urba WJ, Curti BD, et al: The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 10:1141-1152, 1992.
35. Tewari A, Buhles WC Jr, Starnes HF Jr: Preliminary report: Effects of interleukin-1 on platelet counts. Lancet 336:712-714, 1990.
36. Vadhan-Raj S, Kudelka AP, Garrison L, et al: Effects of interleukin-1β on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol 12:707-714, 1994.
37. Smith JW II, Longo DL, Alvord G, et al: The effects of treatment with inlerleukin-1α on platelet recovery after high-dose carboplatin. N Engl J Med 328:756-761, 1993.
38. Tanaka S, Tabuchi S, Watanabe K, et al: Preventive effects of interleukin 1 beta for ACNU-induced myelosuppression in malignant brain tumors: The experimental and preliminary clinical studies. J Neurooncol 14:159-168, 1992.
39. Iizumi T, Sato S, Iiyama T, et al: Recombinant human interleukin-1 beta analogue as a regulator of hematopoiesis in patients receiving chemotherapy for urogenital cancers. Cancer 68:1520-1523, 1991.
40. Crawford J, Ozer H, Stoller R, et al: Reduction of granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 325(3):164-170, 1991.
41. Schulchter L, Neuberg D, Atkins M, et al: A phase I study of interleukin-1 alpha (IL-1) and high dose cyclophosphamide (Cy) in patients with advanced cancer. Proc Am Soc Clin Oncol 13:133, 1994 (abstract).
42. Rinehart J, Delamater EW, Keville L, et al: Corticosteroid modulation of interleukin-1 hematopoietic effects and toxicity in a murine system. Blood 84:1457-1463, 1994.